吉西他滨治疗转移性三阴性乳腺癌的疗效和进展  

Efficacy and advance of gemcitabine in the treatment of metastatic triple negative breast cancer

作　　者：张萍海[1] 王碧芸[2] 陈雅娟[1] 胡夕春[2] 

机构地区：[1]礼来苏州制药有限公司上海分公司医学部,上海200021 [2]复旦大学附属肿瘤医院肿瘤内科,复旦大学上海医学院肿瘤学系,上海200032

出　　处：《中国癌症杂志》2012年第8期627-631,共5页China Oncology

摘　　要：三阴性乳腺癌(triple negative breast cancer,TNBC)作为乳腺癌的一种特殊亚型,特指雌激素受体(estrogen receptor,ER)、孕激素受体(progestin receptor,PR)及人类表皮生长因子2(humanepidermal growth factor receptor-2,HER-2)均为阴性的乳腺癌。目前全球每年约有100多万人被诊断出乳腺癌,TNBC约占乳腺癌的12%～17%。吉西他滨作为一种抗代谢类肿瘤药物,以其特有的作用机制,与其它多种抗肿瘤药物联合用于治疗晚期TNBC。本文总结了国内外相关临床研究,完整地对含吉西他滨的联合治疗在转移性TNBC中的疗效和进展作一综述。Triple negative breast cancer （TNBC）, as a special type of breast cancer, is characterized by lack of expression of estrogen, progesterone and epidermal growth factor receptors on the surface of tumor cells. At present, it is estimated that about one million people had diagnosed with breast cancer annually around the world, of which TNBC accounts for approximately 12%-17% of all the breast cancer cases. Gemcitabine is an anti-metabolite anti-tumor drug with unique mechanism of action. It is used in combination with many other anti-cancer drugs for treatment of advanced TNBC. This review intends to comprehensively demonstrate the efficacy and advance of gemcitabine combination therapies in metastatic TNBC based on the analysis of related clinical studies conducted at home and abroad.

关 键 词：吉西他滨 三阴性乳腺癌 疗效 进展 

分 类 号：R737.9[医药卫生—肿瘤]